USANA Health Sciences arrives at its May 20 earnings date with a quietly shifting positioning backdrop — short sellers who were aggressively building in mid-April have been covering steadily, while options traders have pulled back from the defensive extremes seen just weeks ago.
The short interest story has two distinct chapters this month. Through mid-April, shorts were piling in hard: SI % of free float climbed to nearly 5.6% by April 21, its highest point in the 30-day window. Then the tide turned. Covering has been consistent since then, with SI % FF now back to 4.9% — a meaningful retreat but still material enough to keep this a watched name. The move in shares short tracks a similar pattern: from a peak of around 547,000 shares short in late April to roughly 477,000 by May 5. That's a decline of about 13% from the high in under two weeks. Cost to borrow briefly spiked on April 6 to over 4.3% before settling back. It is now running at about 1.5%, broadly in line with where it sat through March. Availability remains loose by any standard — with a 52-week availability peak of just 8.4% on the utilisation side, there is no squeeze dynamic in the lending market right now. Short sellers face little friction if they want to maintain or rebuild positions.
Options positioning has shifted in a notably less bearish direction. The put/call ratio has dropped to 1.02, running about one standard deviation below its 20-day average of 1.17. That's a marked contrast to the readings above 1.35 that persisted through much of March and early April. The 52-week range runs from a low of 0.20 to a high of 2.43, so the current reading is close to the midpoint — neither aggressively hedged nor nakedly bullish. The direction of travel over the past month, though, is clear: options traders have been steadily unwinding defensive positions as the stock recovered. USNA has gained 14% over the past month to close at $19.26, clawing back losses from a rough first quarter. The one-week print is down a modest 1.3%, with Tuesday seeing a 3.8% bounce.
The Street picture is thin and stale. The only active coverage in the data comes from DA Davidson, which has maintained a Neutral rating through multiple target adjustments stretching back to 2022 — the most recent change, in February 2025, trimmed the target to $36 from $38. With the stock now trading at $19.26, that target implies substantial upside on paper, but the target was set when the stock was trading at a very different level, and the coverage has not been updated since October 2025. Treat that $36 target as a historical artefact rather than a live call. The ORTEX short score of 39.7 ranks in the 36th percentile, consistent with a name that carries moderate but not extreme short-side attention. The days-to-cover rank at the 79th percentile is more notable — it suggests that relative to the stock's trading volume, covering any existing short position would take comparatively longer than for most peers.
Ownership is concentrated in a way that shapes the supply picture. Founder Myron Wentz holds over 40% of shares outstanding and has not changed his position. The rest of the register is split among quantitative and passive managers, with Renaissance Technologies, BlackRock, Pzena, and Vanguard each holding around 5-6%. Nantahala Capital Management is worth flagging — it entered the register in the second half of 2025 with a position of 585,000 shares, representing about 3.2% of the company. That kind of fresh institutional entry into a small-cap name with a concentrated founder shareholder is often a signal of a value thesis. Recent insider activity was largely routine: a round of director stock awards on April 23, accompanied by small open-market sells — none exceeding $13,000 — to cover tax obligations. Nothing directionally meaningful.
Closest peers HLF and NUS both gained on Tuesday — up 2.8% and 4.0% respectively — broadly in line with USNA's own 3.8% bounce. On the week, the peer group is mixed: EL stands out with a 7.5% gain, while ELF has shed 5.7%. USNA's modest weekly decline of 1.3% puts it roughly in the middle of the pack. The next confirmed catalyst is the Q1 earnings release scheduled for May 20. The most recent print, on April 28, saw the stock fall 3.4% on the day before recovering to a near-flat finish over the following week. That single-event reaction is the relevant reference point heading into the next release — how positioning and sentiment respond in the two weeks ahead will be the key thing to track.
See the live data behind this article on ORTEX.
Open USNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
